Notice of Change in Key Dates and Application Types for RFA-DA-23-001, "Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)"
Notice Number:
NOT-DA-21-073

Key Dates

Release Date:

August 17, 2021

Related Announcements

RFA-DA-23-001 - Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to alert potential applicants to a change in Key Dates and Application Types Allowed in, RFA-DA-23-001, "Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)".

The following sections of RFA-DA-23-001, "Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)".

Currently Reads:

Part 1. Key Dates

Open Date (Earliest Submission Date)

July 11, 2022

Letter of Intent Due Date(s)

July 11, 2022

Application Due Date

New

Not Applicable

Renewal / Resubmission / Revision (as allowed)

Not Applicable

AIDS

August 11, 2022

Review and Award Cycles

Scientific Merit Review

November 2022

Advisory Council Review

January 2023

Earliest Start Date

April 2023

Expiration Date

August 12, 2022

Section II. Award Information

Application Types Allowed

New

Modified to Read (changes shown in bold italics):

Part 1. Key Dates

Open Date (Earliest Submission Date)

August 16, 2021


Letter of Intent Due Date(s)30 days prior to the application due date

Application Due Date

New

Only accepting applications for the AIDS Application Due Date(s) listed below.

Renewal / Resubmission / Revision (as allowed)

September 16, 2021, August 11, 2022

AIDS

September 16, 2021, August 11, 2022

Review and Award Cycles

Scientific Merit Review

November 2021, November 2022

Advisory Council Review

January 2022, January 2023

Earliest Start Date

April 2022

Expiration Date

August 12, 2022

Section II. Award Information

Application Types Allowed

New, Resubmissions


All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Vasundhara Varthakavi, DVM, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email: vasundhara.varthakavi@nih.gov

Yu (Woody) Lin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1318
Email: ylin1@mail.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices